Organisation paid for research Program year 2023 Source: CMS Open Payments

Compass Research

Neither a doctor nor a teaching hospital

Research payments

$6,015,445

66 payments

Through program year 2023, Compass Research is reported as receiving $6,015,445 in research payments, across 66 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $900 1
2022 Research $193,724 3
2021 Research $256,491 11
2020 Research $540,732 10
2019 Research $5,023,597 41

Breakdown

Who paid Research payments · program years 2019–2023
  1. Novartis Pharmaceuticals Corporation $5,140,489 18 payments
  2. AstraZeneca UK Limited $595,878 7 payments
  3. Allergan Inc. $236,729 28 payments
  4. Nevro Corp. $31,314 11 payments
  5. Flexion Therapeutics, Inc. $10,135 1 payment
  6. E.R. Squibb & Sons, L.L.C. $900 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $2,600,145 8 payments
  2. A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $2,391,737 5 payments
  3. A Phase I Randomized, Single blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects with Diabetes Type 2 $592,990 5 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $187,065 21 payments
  5. Prospective Observational Cohort Study on Natural Disease Progression and Burden Across the Entire Alzheimer?S Spectrum (Imap Study) $75,270 2 payments
  6. A Phase 1 Open Label Single Dose Multi Center Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor Ljn452 in Subjects With Mild Moderate Or Severe Hepatic Impairment Compared to Healthy Control Subjects $71,681 2 payments
  7. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $49,664 7 payments
  8. Chronic Peripheral Polyneuropathy Randomized Trial $27,373 9 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis $10,135 1 payment
  10. A Phase II Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer ORION $2,888 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record